News: HER2-positive breast cancer

Arteaga Earns Komen Award

Friday, October 7th, 2011

Carlos L. Arteaga, M.D., professor of Medicine and Cancer Biology and associate director for Clinical Research at Vanderbilt-Ingram Cancer Center (VICC), has been named one of the winners of this year’s Susan G. Komen for the Cure Brinker Awards for Scientific Distinction. The Brinker Awards for Scientific Distinction were established in 1992 to recognize the efforts of […]

Breast Cancer and Personalized Medicine

Wednesday, October 5th, 2011

Dr. Carlos Arteaga, director of the Vanderbilt-Ingram Cancer Center’s breast cancer program, describes how advances in personalized cancer medicine contributes to breast cancer treatment.

Breast Cancer Study Combines Therapies

Friday, March 18th, 2011

Combining targeted therapies might be required for maximum anti-tumor activity when treating HER2-positive breast cancers, according to two new studies by Vanderbilt-Ingram Cancer Center (VICC) investigators. The findings, reported in two papers in the Proceedings of the National Academy of Sciences (PNAS), suggest that upregulation of the HER3 receptor limits the effectiveness of two classes […]